CDTI invests in the InceptionBio fund, launched by Ysios to support the creation of biotech companies

The SICC Innvierte fund of CDTI Innovación invests in InceptionBio, a fund aimed at promoting the creation of biotechnology companies and the development of early-stage technology transfer projects.

With this investment, CDTI Innovación reaffirms its commitment to accelerating technology transfer, fostering the creation of new technology-based companies with high growth potential, and strengthening the competitiveness of the Spanish R&D system.

INCEPTIONBIO INNVIERTE, FCRE (InceptionBio) is a new fund launched by Ysios Capital, a leading European life sciences venture capital manager, to support the creation of biotech companies and the development of early-stage projects.

The first close took place last March and included the participation of CDTI Innovación, through Innvierte, with a commitment of €70.56 million.

InceptionBio will focus on identifying, developing, and building new companies based on excellent science, with a special emphasis on Spain. The fund will primarily invest in technology transfer projects and early-stage companies, with the aim of accelerating technology transfer by working closely with universities, research centers, and entrepreneurs to transform scientific discoveries into new therapies with patient impact.

InceptionBio’s strategy combines the creation of new companies from scientific assets developed in universities and research centers with the identification and attraction of international assets with potential to be developed from Spain through the creation of new companies. In this way, it seeks to actively contribute to strengthening the national ecosystem and positioning Spain as a reference biotech hub.

The fund already has a pipeline of investment opportunities in an advanced stage of analysis. As part of its deployment plan, InceptionBio aims to establish at least three new biotech companies throughout 2026.

The support of CDTI Innovación, through Innvierte, reinforces public-private collaboration in a key area for the development of the Spanish biotech ecosystem and will help accelerate technology transfer, foster the creation of new high-growth technology-based companies, and strengthen the competitiveness of the Spanish R&D system.

Ysios Capital

Ysios Capital is a leading Spanish venture capital firm that provides funding to highly innovative life sciences companies developing treatments for diseases with significant unmet medical needs. With offices in San Sebastián and Barcelona, it has a diverse team of professionals whose goal is to transform capital into medical breakthroughs, generating both financial returns and positive social impact.

Founded in 2008, the firm manages more than €450 million in assets across three funds. It also acts as investment advisor to the listed fund Telescope Biotech Fund, managed by Andbank Wealth Management. Throughout its history, Ysios Capital has invested in more than 40 biotech companies and completed 6 NASDAQ exits and 11 M&A divestments, establishing itself as one of Europe’s leading sector investors.

With InceptionBio, the firm expands its ability to support biomedical innovation across the entire value chain, from very early stages, complementing its investment strategy. Its team also brings extensive experience in innovation, entrepreneurship, and life sciences company development, having participated in the creation, management, and growth of multiple biotech companies over the past 20 years.

Innvierte

Innvierte is an initiative aimed at promoting business innovation by supporting venture capital investment in technology-based or innovative companies. The program is implemented through the closed-ended collective investment scheme Innvierte Economía Sostenible SICC S.M.E., S.A., self-managed and supervised by the Spanish National Securities Market Commission (CNMV), with CDTI Innovation as its sole shareholder.

To date, CDTI Innovación has committed, through Innvierte, €3,478.5 million across 61 investment vehicles and, through its co-investment line, has directly committed €866.1 million in 197 companies.

Innvierte is part of the Spanish Strategy for Science, Technology and Innovation 2021–2027, approved by the Council of Ministers in September 2020. This strategy sets out the objectives, reforms, and measures across the entire R&D&I ecosystem to drive growth and impact, and is one of the pillars of the Government’s innovation policy in the coming years.

CDTI Innovación

The Centre for the Development of Industrial Technology and Innovation (CDTI E.P.E.) is the innovation agency of the Spanish Ministry of Science, Innovation and Universities, responsible for promoting technological innovation in the business sector. Its mission is to ensure that the Spanish business ecosystem generates and transforms scientific and technical knowledge into globally competitive, sustainable, and inclusive growth. In 2025, under its Strategic Plan 2024–2027, CDTI provided more than €2 billion in support to Spanish companies and startups

More info:

Web: www.cdti.es
Linkedin: https://www.linkedin.com/company/cdti/
X: https://x.com/CDTI_innovacion
Youtube: https://www.youtube.com/user/CDTIoficial
Web: www.innvierte.es

Ysios Capital:
Web: www.ysioscapital.com
LinkedIn: https://www.linkedin.com/company/ysios-capital
X: https://x.com/YsiosCapital